secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2024-06-03T23:59:59+00:00
Accession:  0001193125-24-152380
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

WTX-124 Phase 1/1b shows 3 objective responses (1 CR) in checkpoint-refractory solid tumors
--------------------------------------------------------------------------------

- 3 objective responses out of 35 monotherapy-treated patients: 1 confirmed complete response, 2 partial responses.
- All responding patients had 100% target lesion regression; responses durable at recommended dose for expansion (RDE).
- RDE selected as 18 mg IV every 2 weeks; three expansion arms opened in RCC, melanoma, cutaneous SCC.
- WTX-124 + pembrolizumab combination well-tolerated with enhanced T-cell activation in tumors; no new safety signals.
- Company plans to engage regulators on potential monotherapy accelerated approval pathway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000119312524152380/0001193125-24-152380-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000119312524152380/d800910d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-152380

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer